News of Omnipod Discover app to organise insulin and glucose data plus rollout of Omnipod 5 in the Middle East.
Insulet has reported several developments for its Omnipod insulin pump systems during early 2026 as the company continues to expand adoption of hybrid-closed loop technology.
Product updates
Insulet has received regulatory clearance for updates to the Omnipod 5 algorithm, including a lower glucose target option of 100 mg/dL (5.6 mmol/L). The updated algorithm is expected to roll out during 2026.
The company is also developing the next generation of its platform, known as Omnipod 6. The planned system is expected to include an adaptive algorithm that learns from a user’s insulin needs over time in order to adjust insulin delivery more precisely. According to reporting highlighted by MedTech Dive, development is ongoing with a launch expected later in the decade.
Omnipod Discover
Insulet has launched a new digital platform called Omnipod Discover, which organises insulin and glucose data to support people with diabetes and healthcare professionals reviewing treatment data.
UK context
In the UK, Omnipod 5 is available as part of hybrid-closed loop therapy for some people with type 1 diabetes.
The system can integrate with several CGM sensors including Dexcom G6, Dexcom G7 and FreeStyle Libre 2 Plus, although NHS funding decisions for different combinations may vary locally.
International Developments
International expansion continues to be an important part of Insulet’s growth strategy with Omnipod now used by more than 500,000 people across more than 25 countries worldwide.
In February 2026, Insulet launched Omnipod 5 and the Omnipod Discover data platform in several Middle Eastern markets including Saudi Arabia, the United Arab Emirates, Kuwait and Qatar.
The launch expands access to hybrid-closed loop technology across the Gulf region, where diabetes prevalence is among the highest in the world.
Elsewhere, Omnipod is extending compatibility with different CGM systems. In the UK and the Netherlands, Omnipod 5 now integrates with Dexcom G7.
Market growth
Insulet has indicated that demand for its patch-pump systems continues to grow. The company expects Omnipod product revenue to increase by more than 20% during 2026 as adoption expands among people with both type 1 and type 2 diabetes.
The Omnipod 5 system is designed to automatically adjust insulin delivery every five minutes based on glucose readings from a connected CGM. The device is worn on the body and delivers insulin continuously for up to three days without tubing.
__________
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website whatcgm.comdoes not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.